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Purpose:  Endobronchial  metastases  from  extrapulmonary  solid  tumors  are  a  rare  event and  currently
available  epidemiological  and  clinico-pathological  data  mainly  derive  from  anecdotal  case  reports.
Methods:  A series  of  174  consecutive  cases  of endobronchial  metastases  from  extrathoracic  solid  tumors
were  collected  over  a period  of 18 years.  Immunohistochemistry  was  performed  in  115 cases.  Complete
imaging  features  were  available  in 81 patients,  and  analysis  of the  latency  period  between  primitive
tumor  diagnosis  and occurrence  of  endobronchial  metastasis  was  obtained.
Results:  Among  all bronchoscopic  examinations  performed  in  the same  period  for  malignancy,  a  mean  of
5.6 cases  per  year  consisted  of endobronchial  metastases  (range  2–17  cases),  with  a statistically  signiﬁ-
cant  increase  when  comparing  the  periods  1992–2000  (65 cases,  37%)  and  2001–2009  (109  cases,  63%)
(p  =  0.05).  Overall,  4%  of  endobronchial  biopsies  for suspected  malignancy  disclosed  an  endobronchial
metastasis from  extrapulmonary  tumor.  Breast  (52  cases,  30%),  colorectal  (42 cases,  24%), renal  (14%), gas-
tric (6%)  and  prostate  (4.5%)  cancers  and  melanoma  (4.5%)  were  the  most  common  metastatic  neoplasms
presenting  as  endobronchial  mass.  One-hundred  ﬁfty-four  cases  were  identiﬁed  after  the primitive  tumor
diagnosis  (metachronous  cases,  89%),  11  cases  were  simultaneously  evidenced  in extrapulmonary  and
endobronchial  sites  (synchronous  cases,  6%),  while  9 occult  metastatic  cases  (5%)  ﬁrst  presented  as  endo-
bronchial  mass  (anachronous  cases).  Overall,  mean  latency  from  extrapulmonary  tumor  diagnosis  and
endobronchial  metastasis  was  136  months  (range,  1–300  months).  The  most  frequent  symptoms  were
dyspnea  (23%),  cough  (15%)  and haemoptysis  (12%),  while  26%  of  patients  were  totally  asymptomatic.
At  radiology,  53% presented  as  multiple  pulmonary  nodules,  while  other  cases  presented  as  hilar  and
mediastinal  mass,  single  peripheral  nodule,  atelectasis  or pleural  effusion.
Conclusions:  Endobronchial  metastases  from  extrapulmonary  tumors  account  for  about  4% of  all  bron-
choscopic  biopsies  performed  for suspected  malignancy  and  in  5% of the  cases  the metastasis  is  the  ﬁrst
manifestation  of the neoplasm.
© 2014 Elsevier  Ireland  Ltd.  All  rights  reserved.. IntroductionMetastatic disease to the lungs is a common occurrence in
outine oncologic practice and 20–50% of primary extrapulmonary
olid malignancies show pulmonary metastases during their
∗ Corresponding author at: Respiratory Diseases Clinic, Azienda Ospedaliero-
niversitaria Policlinico, via del Pozzo, 71, 41124 Modena, Italy.
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ttp://dx.doi.org/10.1016/j.lungcan.2014.03.005
169-5002/© 2014 Elsevier Ireland Ltd. All rights reserved.biologic course [1,2]. Among all clinico-radiologic presentations,
the ﬁnding of metastatic tumors manifesting as endobronchial
masses is a rare and possibly underestimated event.
Epidemiological studies show a broadly variable incidence of
endobronchial metastases ranging from 2 to 50% depending on
several factors, including the different clinical settings and/or the
length of the period of time considered, the ethnic background
which is signiﬁcantly associated with different incidences of tumor
types, as well as the criteria used to identify this unusual occur-
rence [3–6]. Kiryu et al. [7] proposed a 4 types classiﬁcation of the
development pattern of endobronchial metastases, as follows: type
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: direct metastasis to the bronchus; type II: bronchial invasion by
arenchymal lesion; type III: bronchial invasion by mediastinal or
ilar lymph node metastasis; type IV: peripheral lesion extending
long the proximal bronchus. However, the great majority of endo-
ronchial metastases reported in the literature are of type I due to
he difﬁculty to discriminate these 4 patterns with certainty.
On the clinical ground, it is noteworthy that several patients
ay  be totally asymptomatic and radiological ﬁndings are not
articularly helpful in hindering differential diagnosis between
ndobronchial primary and metastatic tumors [6].
Among solid tumors occurring as endobronchial metastases,
arcinomas from breast, kidney and colon-rectum are the most
ommonly encountered [4,7–30]. The timeframe between primi-
ive tumor diagnosis and appearance of endobronchial metastases
s quite variable although usually long, with an average of 50
onths [7–9]. Finally, endobronchial metastases may  generally
ollow identiﬁcation of the primary site (metachronous cases)
r more rarely precede (anachronous) or simultaneously reveal
synchronous) the primary malignancy discovery. Currently, our
nowledge on endobronchial metastases from extrapulmonary
olid tumors derive from case reports and few studies with a limited
eries of cases or conducted by using different clinical and radiolog-
cal data collection methods, then resulting in fragmented and/or
ontroversial data.
The aim of our study is to draw a more homogeneous epidemio-
ogical, clinico-radiologic and pathologic scenario of endobronchial
etastases through a careful retrospective analysis of 174 consec-
tive cases along a period of 18 years collected from 2 different
nstitutions. The results herein presented were then compared with
xperiences previously appeared in the literature, in the hope to
dentify helpful features for suspecting metastatic disease when
ealing with endobronchial masses.
. Materials and methods
A series of 174 consecutive cases of endobronchial metasta-
is from extrapulmonary tumors were collected from the Units of
athologic Anatomy and Pulmonology of the Azienda Ospedaliero-
niversitaria Policlinico of Modena and the Azienda Ospedaliera
t. Maria Nuova of Reggio Emilia. Diagnoses were made between
anuary 1992 and December 2009 and all cases were ﬁrst indepen-
ently diagnosed and then reviewed at a multiheaded microscope
y two expert pulmonary pathologists (AC, GR). Endobronchial
etastasis was recorded when a bronchoscopically visible, extra-
ulmonary neoplasm metastasized to the central or segmental
ronchus. Lymphoproliferative malignancies were excluded from
he study, since lymphomas or plasma cell neoplasms may  fre-
uently arise from the mediastinum or involve lymph nodes of
his anatomic site then directly invading the bronchial structures.
ll cases consisted of bronchial biopsies that were formalin-
xed and parafﬁn-embedded. In all cases, 4-micron sections
rom the parafﬁn-block were performed for routine staining with
ematoxylin–eosin. However, in 115 cases (66%) the diagnosis
equired further analysis by means of immunohistochemical stains.
hen required, immunohistochemistry was performed using an
utomated immunostainer (Benchmark, Ventana, Tucson, AZ). Both
nstitutions independently performed immunohistochemical anal-
sis, but using the same type of instruments as well as the same
ntibody clones. The panel of antibodies in each single case was
ppropriately selected depending on the differential diagnosis.
he primary antibodies used in the study were the following:
hyroid Transcription Factor-1/TTF-1 (clone 8G7G3/3, Ventana,
rediluted), Thyroglobulin (clone 2H11/6E1, Ventana, prediluted),
DX2 (clone EPR2764Y, Ventana, prediluted), CD10 (clone 013,
entana, prediluted), estrogen receptors (clone SP1, Ventana;cer 84 (2014) 222–228 223
prediluted), progesterone receptors (clone 1E2, Ventana, predi-
luted), Wilms’Tumor-1/WT-1 (clone 6F-H2, Ventana, prediluted),
calretinin (clone SP65, Ventana, prediluted), S100 (polyclona, Ven-
tana, prediluted), melan-A (clone MART-1, Ventana, prediluted),
PSA (ER PR8, Ventana, prediluted), smooth-muscle-actin (clone
1A4, Ventana, prediluted), desmin (clone DE-R-11, Ventana, predi-
luted), pan-cytokeratins (clone AE1/AE3, Ventana, prediluted),
CD34 (clone QB-END/10, Ventana, prediluted), CD31 (clone JC/70A,
Ventana, prediluted) (6F-H2, Ventana, preduted), p63 (clone 4A4,
Ventana, prediluted), calcitonin (polyclonal, Ventana, prediluted),
Epithelial Membrane Antigen/EMA (clone E29, Ventana, predi-
luted).
Clinical data (sex, age, symptoms, time lapse between primary
and metastatic tumors, type of primary extrapulmonary tumor)
were available in all cases, while detailed imaging features were
obtained in 81 cases.
2.1. Statistical analysis
Contingency tables were used for descriptive and comparative
statistical analysis of collected data, and signiﬁcance was evalu-
ated with Pearson’s chi-squared test and Fisher’s test. All statistical
calculations were performed using SPSS 13.0 software (Statistical
Package for the Social Sciences, Chicago, IL). Differences were con-
sidered statistically signiﬁcant for probability < 0.05.
The study was conducted in accordance with the precepts of the
Helsinki Declaration and all recorded data were handled anony-
mously.
3. Results
The baseline characteristics of the entire case series are summa-
rized in Table 1.
The case histories collected included 174 cases of endobronchial
metastasis, with a slight prevalence of male patients (54%), an
average age of 67 years and a range between 27 and 89 years. Diag-
nosis of endobronchial metastasis was  obtained after a diagnosis
of extrapulmonary tumor (metachronous cases) in 154 cases (89%),
while in 11 cases (6%) the tumor was  detected on an endobronchial
level simultaneously to that on the extrapulmonary site (syn-
chronous cases). In the remaining 9 cases (5%), the endobronchial
metastasis was the ﬁrst manifestation of an occult extrapulmonary
tumor (anachronous cases). Distribution of the primary tumors
and time of endobronchial metastasis occurrence is summarized
in Table 2.
It should be noticed that around 50% of anachronous cases were
secondary to renal carcinoma. On average, in the overall 18-year
period, 5.6 cases of endobronchial metastasis were observed per
year (range: 2–17 cases), with statistically signiﬁcant differences
for the periods between 1992–2000 (65 cases, 37%) and 2001–2009
(109 cases, 63%) (p = 0.05).
To allow a better understanding on the extent of the issue and
on how this could inﬂuence the clinician’s activity, we  referred to
the bronchoscopy service of the Azienda Ospedaliero-Universitaria
Policlinico in Modena to review all the reports of the broncho-
scopic investigations performed between 2006 and 2009. In these
4 years, 4208 procedures were performed, 781 (18.5%) on patients
for whom endoscopic ﬁndings were suggestive of tumors in the
tracheobronchial tree. Of note, 31 out of 781 (4%) broncoscopic
examinations revealed endobronchial metastases from nontho-
racic malignancies.Bronchoscopy was performed for the following reasons: radio-
logical features (nodules, masses and hilar-mediastinal and/or
peripheral lymphadenomegaly), atelectasis, and symptoms such
as dyspnea, haemoptysis and persistent cough. Biopsies were
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Table  1
Clinico-pathologic characteristics of patients with endobronchial metastasis.
Variable Frequency (%)
Sex and age
Male (mean age: 69 years) 94 (54)
Female (mean age: 66 years) 80 (46)
Symptoms
Asymptomatic 42 (24)
Cough 38 (22)
Dyspnea 30 (17)
Haemoptysis 20 (12)
Dysphonia 2 (1)
Not available 24 (14)
Primary tumors
Breast 52 (30)
Colon-rectum 42 (24)
Kidney 24 (14)
Stomach 11 (6)
Prostate 8 (4.5)
Melanoma 8 (4.5)
Thyroid 5a (3)
Endometrium 3 (2)
Liver 3 (2)
Small bowel 2 (1)
Ovary 2 (1)
Leiomyosarcoma 3b (2)
Bladder 2 (1)
Renal pelvis 1 (0.5)
Mesothelioma 1 (0.5)
Solitary ﬁbrous tumor 1 (0.5)
Vagina 1 (0.5)
Cervix 1 (0.5)
Esophagus 1 (0.5)
Liposarcoma spermatic cord 1 (0.5)
Nasopharynx 1 (0.5)
Meningioma 1 (0.5)
Type of metastasis
Metachronous 154 (89)
Synchronous 11 (6)
Anachronous 9 (5)
a 3 papillary type, 1 each anaplastic and medullary type.
b 2 cutaneous type and 1 uterine type.
Table 2
Distribution of metastasis primary and time of endobronchial metastasis
occurrence.
Primary tumors Metachronous Synchronous Anachronous
154 (89%) 11 (6%) 9 (5%)
Breast = 52 48 2 2
Colon-rectum = 42 40 2 –
Kidney = 24 19 1 4
Stomach = 11 6 4 1
Prostate = 8 7 – 1
Melanoma = 8 8 – –
Thyroid = 5a 5 – –
Endometrium = 3 3 – –
Liver = 3 3 – –
Small bowel = 2 2 – –
Ovary = 2 2 – –
Leiomyosarcoma = 3b 3 – –
Bladder = 2 1 1 –
Renal pelvis = 1 – – 1
Mesothelioma = 1 1 – –
Solitary ﬁbrous tumor = 1 1 – –
Vagina = 1 1 – –
Cervix = 1 1 – –
Esophagus = 1 – 1 –
Liposarcoma spermatic cord = 1 1 – –
Nasopharynx = 1 1 – –
Meningioma = 1 1 – –
a 3 papillary type, 1 each anaplastic and medullary type.
b 2 cutaneous type and 1 uterine type.cer 84 (2014) 222–228
performed on macroscopically visible endobronchial lesions with-
out complementary methods.
On the full cohort of 174 patients, extrapulmonary tumors
most often resulting in endobronchial metastasis included breast
carcinoma (52 cases, 30%), colorectal carcinoma (42 cases, 24%),
renal carcinoma (24 cases, 14%), stomach carcinoma (11 cases, 6%),
prostate carcinoma (9 cases, 5%), and melanoma (8 cases, 4.5%).
Although endobronchial metastases from epithelial-derived
tumors (carcinomas) signiﬁcantly overridden mesenchymal neo-
plasms (5 cases) and melanomas (8 cases), it is important to notice
that virtually all types of solid tumor can metastasize into the
bronchial tree. Supporting this, three types of tumor included in the
current series (liposarcoma of the spermatic cord, solitary ﬁbrous
tumor and cutaneous leiomyosarcoma) have not so far reported in
the literature (Figs. 1 and 2).
Although not statistically signiﬁcant, endobronchial metastases
more frequently affected the right (102 cases, 59%) than the left
bronchus (72 cases, 41%) (p = 0.07).
The overall median latency period between the detection
of extrapulmonary tumor and the occurrence of endobronchial
metastasis was  136 months (range, 1–300 months). Among
the most frequent extrapulmonary malignancies leading to
endobronchial metastasis, a signiﬁcant difference was  observed
between breast carcinoma (median, 86 months; range, 1–300
months) or renal carcinoma (median, 82 months; range, 18–270
months) and colorectal carcinoma (median, 53 months; range,
9–168 months) (p < 0.001) (Fig. 3).
3.1. Clinico-radiologic features
The patterns of clinical and radiological presentation, ordered
by frequency, for the 81 analyzed patients were summarized in
Table 3 (supplement material) and Table 4 (supplement material),
respectively. Of the collected case histories, 21 patients (26%) were
asymptomatic, while the most common symptoms reported were
dyspnea, cough and haemoptysis, in 19 (23%), 15 (19%) and 10
(12%) cases respectively. In one single case the only symptom was
dysphonia secondary to left laryngeal nerve compression. For 16
patients, the presenting symptoms were not reported in clinical
charts.
See Tables 3 and 4 as supplementary ﬁles. Supplementary mate-
rial related to this article can be found, in the online version, at
http://dx.doi.org/10.1016/j.lungcan.2014.03.005.
Only standard chest x-rays were available for 7 patients, while
chest x-rays and CT scans were available for the remaining patients.
“Nodules” were deﬁned as lesions with a maximum diameter
equal to or less than 30 mm;  “masses” were deﬁned as lesions
with a diameter over 30 mm;  “lymphadenomegaly” was deﬁned
as hilar-mediastinal lymph nodes with a maximum diameter
over 10 mm.  Multiple nodules were present in 43 cases (53%),
hilar-mediastinal lymphadenomegaly in 38 cases (47%), a periph-
eral mass in 24 cases (30%), atelectasis in 23 cases (28%), pleural
effusion in 19 cases (23%) and a hilar-mediastinal mass in 13 cases
(16%).
4. Discussion
Lungs are the commonest site of metastatic deposits from
extra-pulmonary malignancies, but metastases presenting as endo-
bronchial growth are quite unusual and epidemiologic and/or
clinic-pathologic data on large homogeneous series are lacking.
The present study collected the largest series to date of con-
secutive endobronchial metastases from extrapulmonary tumors
disclosed in routine practice without selection biases (174 cases),
underlying the clinically relevant occurrence of this phenomenon.
A. Marchioni et al. / Lung Cancer 84 (2014) 222–228 225
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aig. 1. Endobronchial metastasis from spermatic cord liposarcoma. CT scan (A) sho
ellowish appearance at bronchoscopy (B). Histology (C) reveals a haphazard prolif
mong all bronchoscopic procedures performed in the suspicion
f lung tumor, the overall incidence was about 4% per year, a
gure higher than 1% reported by Kreisman et al. in 1983 [31].
owever, this result is difﬁcult to compare with epidemiological
eferences of other studies, due to the variability of classiﬁcation
riteria in considering endobronchial metastasis, the length and
ig. 2. Endobronchial metastasis from malignant solitary ﬁbrous tumor of the pleura. CT 
 segmental bronchus (B). Histology shows a submucosal spindle cell proliferation (C) exolitary nodule entirely occupying the main left bronchus with smooth margins and
n of atypical spindled-shaped cells with clear cytoplasm.
type of the period of time considered as well as the different ethni-
cal background of the study including malignancies with different
incidence. It could be reasonable to assume that the increasing
number of diagnostic procedures, including bronchoscopy exam-
inations, performed in the current work-up of oncologic patients
has lead to higher possibility to disclose endobronchial metastases.
scan (A) displays a unique rounded nodule of the lower left lobe partially occluding
pressing CD34 (D) at immunohistochemistry.
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F
big. 3. Distribution of the temporal latency between the occurrence of
ndobronchial metastases and primary tumors among the most represented malig-
ancies.
In literature, endobronchial metastases generally were reported
s single case descriptions or very limited case series [4,8,32,33].
lthough the development of pulmonary metastases is in fact a
ommon occurrence, their endobronchial location is considered
o be a rare event. Frequency estimates are still based on rather
utdated studies and primarily on autopsy series [3,6], but it can
ary considerably depending on the study and the deﬁnition of
ndobronchial metastasis, ranging from 2 to 50% [3,4,12–16,32,33].
herefore, the epidemiology of this type of metastasis is still quite
nclear.
In our bronchoscopy service, endobronchial metastasis was
iagnosed in 4% of the bioptic procedures performed as a result of
uspected malignancy. Considering that bronchoscopy is not rou-
inely performed on all patients with tumors, it may  be implied
hat both incidence and frequency of endobronchial metastases are
robably underestimated.
The latency period between primary extrapulmonary tumor and
ndobronchial metastasis may  be very long [36].
For patients presenting with tumors that most commonly cause
ndobronchial metastasis, the systematic use of chest CT scans and
ig. 4. Unknown renal cell carcinoma presenting as endobronchial metastasis. CT scan (
ronchus (B) as an ulcerated polypoid lesion (C) consisting of a submucosal clear cells procer 84 (2014) 222–228
bronchoscopy could be useful. In particular, breast, colon and renal
lesions are reported in the literature as being most often asso-
ciated with endobronchial metastasis [17–24,32,33]. This ﬁnding
was conﬁrmed in our study that reported how tumors arising in
these sites account for over 60% on the total (see Table 1). For gas-
tric cancer, prostate carcinoma and melanoma, accounting for 16%
of endobronchial metastases in our case series, careful monitoring
of the tracheobronchial tract could also facilitate the detection of
secondary lesions in a greater number of cases.
Another interesting aspect concerns the capacity of virtually
all solid tumors of various cell differentiation to produce endo-
bronchial metastases. So far, this fact was only documented by
sporadic single case descriptions [25–30]. Regarding the clini-
cal/radiological presentation, collected data strongly conﬁrm the
literature ﬁndings [3–6,10,11,32,33], and reassert evidence of a
presentation that is difﬁcult to differentiate from that of a pri-
mary pulmonary tumor. Among 81 patients for which complete
clinico-radiologic data were available, 21 (26%) were entirely
asymptomatic. Previous studies, depending on the case histories
included, reported a highly variable percentage of asymptomatic
patients, ranging from 0 to 52% of cases [8–10,14,32,33]. When
present, dyspnea, cough and haemoptysis were the most common
symptoms. Radiological ﬁndings evidenced multiple pulmonary
nodules and hilar-mediastinal lymphadenomegaly as the most fre-
quent conditions, detected in about half of the examined cases.
A peripheral mass and atelectasis were reported in about 1/3 of
cases, while pleural effusion and hilar-mediastinal masses were
less common.
In some cases, radiological differential analysis vs primitive
tumor was extremely difﬁcult, as showed in Fig. 4 where radio-
logical appearance strikingly suggested a primary lung cancer
presenting as an excavated pulmonary mass, but the patient hadendobronchial metastasis follows the diagnosis of the primary
lesion, with a largely variable time interval between them. Our
data evidenced an average interval of 134 months, with a very
A) evidences an escavated mass involving the left hilar region protruding into the
liferation (D) expressing CD10 at immunohistochemistry (E).
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ide range accounting up to 300 months, this ﬁnding appearing
o be signiﬁcantly discordant when compared to similar observa-
ion in previous studies. Soresen, in a review of already published
ases, reported an interval of 50 months (range 0–300) [9]; Sebahat
videnced a value of 32.8 months (range 0–96) [10]; Kiryu reported
n average interval of 65.3 months [7]; Dursun found a value of 47
onths (range 0–19 years or 0–228 months) [11]. More recently,
ee et al. [32] evidenced a mean interval of 36 months in a case
eries of 43 patients, while Kim et al. [33] found a mean inter-
al of 14 months (range, 0–112 months) in their experience on 18
atients. All these intervals are quite shorter than that observed in
ur study and possibly inﬂuenced by many factors, among which
he larger number of patients and the greater spectrum of histo-
ogic types present in our study. Although metastasis was detected
ollowing the diagnosis of the primary lesion in the great majority
f our cases, the ﬁnding of 5% of cases in which the primary lesion
as unknown when endobronchial biopsy was performed does not
ppear a negligible feature. Four of these anachronous 9 cases were
enal cell carcinomas, while the others consisted of 2 breast cancers,
nd 1 case each of carcinoma from stomach, prostate and upper
rothelial tract (renal pelvis).
Similarly to our results, a previous study on endobronchial
etastases secondary to renal carcinoma evidenced that in 7 out
f 17 patients the endobronchial metastases occurred before the
iagnosis of renal carcinoma [23].
Considering the high incidence and long survival, it is not sur-
rising that, in agreement with previous works on endobronchial
etastases, breast and colon cancers are the most commonly
escribed extrapulmonary malignancies showing this peculiar
ndobronchial growth pattern. However, along a period of 18 years,
e found 174 endobronchial metastases disclosing 22 different his-
ologic types, including also tumor entities previously unreported,
uch as a spermatic cord liposarcoma, a recurrent malignant soli-
ary ﬁbrous tumor, 3 leiomyosarcomas (2 from the skin and 1 from
he uterus) and a meningioma. Pathologists should then be aware
f the occurrence of endobronchial metastases when dealing with
 neoplasm showing an unusual morphology for a primary lung
umor and clinico-radiologic data discrepantly supporting a pul-
onary malignancy (Figs. 1, 2 and 4).
Unfortunately, the perfect panel of immunistains in detecting
rimary vs metastatic tumors or in disclosing the type of metastatic
eoplasms does not exist. The correct diagnosis always requires a
ultidisciplinary approach and should be contextualized in each
ingle case based on clinical data, imaging studies, careful morpho-
ogic examination and appropriate immunohistochemical markers
34,35]. In this study immunomarkers were asked in 115 cases
66%), but pathologists, as well as clinicians, should be aware that
one of the antibodies here employed is absolutely diagnostic per
e. Supporting this fact, the metastatic meningioma was originally
isdiagnosed as squamous cell carcinoma based on imaging stud-
es revealing a single centrally-located nodule, p63 expression and
ack of TTF-1 reactivity. However, the knowledge of a previous
iagnosis of recurrent cerebral meningioma has lead to further sub-
yping tumor cells ﬁnally disclosing progesterone receptors and
MA  expression, then leading to the correct diagnosis of endo-
ronchial metastasis from meningioma.
Recently, Dong et al. [34] introduced the role of FDG PET/CT as
nother helpful diagnostic tool in identifying endobronchial metas-
ases.
In conclusion, the current study represents the largest series
f consecutive extrapulmonary tumors presenting with endo-
ronchial metastases. Summarizing the key points derived from
he current data, it is important to keep in mind that: (1) endo-
ronchial metastases may  occur in about 4% of bronchoscopic
xaminations performed for a suspected neoplasm; (2) a not
nsigniﬁcant rate of endobronchial metastases (5% in our study)
[
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may  be the ﬁrst manifestation of an extra-pulmonary tumor; (3)
virtually all kind of solid tumors may  occasionally metastasize
into the bronchial lumen; (4) up to one third of patients with
endobronchial metastasis may  be asymptomatic or even present
with a radiologic pattern mimicking primary lung cancer.
When endobronchial metastases lead to controversial issues
with clinical implications on diagnostic ground, the close collab-
oration between clinician, radiologist and pathologist is the most
critical step in achieving the correct diagnosis, then preventing
erroneous therapeutic approaches.
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